User profiles for Roslyn J. Francis
 | Roslyn FrancisUniversity of Western Australia Verified email at exix.com Cited by 5596 |
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective …
Background Conventional imaging using CT and bone scan has insufficient sensitivity
when staging men with high-risk localised prostate cancer. We aimed to investigate whether …
when staging men with high-risk localised prostate cancer. We aimed to investigate whether …
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
…, DA Pattison, TH Tan, ID Kirkwood, S Ng, RJ Francis… - The Lancet, 2021 - thelancet.com
Background Lutetium-177 [ 177 Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers
β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity …
β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity …
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate …
Background Previously, results from the TheraP trial showed that treatment with lutetium-177
[ 177 Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response …
[ 177 Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response …
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of …
RJ Francis, MJ Byrne, AA van der Schaaf… - Journal of Nuclear …, 2007 - Soc Nuclear Med
The aim of chemotherapy for mesothelioma is to palliate symptoms and improve survival.
Measuring response using CT is challenging because of the circumferential tumor growth …
Measuring response using CT is challenging because of the circumferential tumor growth …
[HTML][HTML] Post-radioembolization yttrium-90 PET/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres
…, DW Townsend, CA Budgeon, JA Boucek, RJ Francis… - EJNMMI research, 2013 - Springer
Background Coincidence imaging of low-abundance yttrium-90 ( 90 Y) internal pair
production by positron emission tomography with integrated computed tomography (PET/CT) …
production by positron emission tomography with integrated computed tomography (PET/CT) …
TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical …
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177 Lu‐ PSMA ‐617, a novel radiolabelled small molecule that binds with high affinity to …
with 177 Lu‐ PSMA ‐617, a novel radiolabelled small molecule that binds with high affinity to …
A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate …
Background Accurate staging of patients with prostate cancer ( PC a) is important for
therapeutic decision‐making. Relapse after surgery or radiotherapy of curative intent is not …
therapeutic decision‐making. Relapse after surgery or radiotherapy of curative intent is not …
A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters
… Note: AK Nowak and RJ Francis contributed equally to this work. … J Clin Oncol … Eur J Cancer …
TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) …
…, DA Pattison, TH Tan, ID Kirkwood, S Ng, RJ Francis… - 2020 - ascopubs.org
5500 Background: LuPSMA is a radiolabeled small molecule that delivers therapeutic β-radiation
to PSMA-expressing tumors. Encouraging efficacy and safety has been shown in non-…
to PSMA-expressing tumors. Encouraging efficacy and safety has been shown in non-…
Is prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the …
Background Before integrating prostate-specific membrane antigen (PSMA) positron emission
tomography/computed tomography (PET/CT) into routine care, it is important to assess if …
tomography/computed tomography (PET/CT) into routine care, it is important to assess if …